Je was op zoek naar: veckorsstudier (Zweeds - Engels)

i dessa tre 6- veckorsstudier erhölls följande effektresultat vid studiens slut:
in these three 6-week studies, the efficacy results at endpoint were as follows:

panretin har undersökts i två 12- veckorsstudier med sammanlagt 402 patienter med kaposis sarkom.
panretin has been examined in two 12-week studies in patients with kaposi’ s sarcoma, involving a total of 402 patients, where the effectiveness of panretin was compared to that of placebo (a dummy treatment, in this instance the gel without the active substance).

elektrokardiogram togs under 12- veckorsstudier på 755 duloxetinbehandlade patienter med ansträngningsinkontinens och 779 placebobehandlade patienter.
electrocardiograms were obtained from 755 duloxetine-treated patients with sui and 779 placebo- treated patients in 12-week clinical trials.

i dessa 52-veckorsstudier behandlades patienterna i 12 veckor, följt av 40 veckor utan behandling.
in these 52 week duration studies, patients received treatment for 12 weeks, followed by a 40 week non-treatment phase.

ariclaim har undersökts i två 12-veckorsstudier på 809 vuxna diabetespatienter som hade haft smärtor varje dag i minst sex månader.
ariclaim has been studied in two 12-week studies in 809 diabetic adults who had had pain every day for at least six months.

när det gällde behandling av neuropatisk smärta vid diabetes undersöktes ariclaim i två 12- veckorsstudier på 809 vuxna diabetespatienter som haft smärta varje dag i minst sex månader.
for the treatment of diabetic neuropathic pain, ariclaim has been studied in two 12-week studies in 809 diabetic adults who had had pain every day for at least six months.

två dubbelblinda, placebokontrollerade 24-veckorsstudier utfördes för att utvärdera effekten och säkerheten med saxagliptin som monoterapi till patienter med typ 2-diabetes.
two double-blind, placebo-controlled studies of 24-week duration were conducted to evaluate the efficacy and safety of saxagliptin monotherapy in patients with type 2 diabetes.

kliniska biverkningar hos patienter med kronisk hepatit b, som behandlats med telbivudin 600 mg i de sammanslagna 104- veckorsstudierna nv- 02b- 007 globe och nv- 02b- 015 *
clinical adverse reactions in patients with chronic hepatitis b, treated with telbivudine 600 mg in the pooled 104-week nv-02b-007 (globe) and nv-02b-015 studies *